Trial Profile

Phase II adjuvant study of SLATE-001 in high-risk localized tumors (Non-small-cell-lung-cancer, pancreatic cancer and MSS-Colorectal-cancer)

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 18 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SLATE 001 (Primary)
Indications Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer
Focus Therapeutic Use

11 May 2023 According to a Gritstone Oncology media release, company is deferring the initiation of a randomized Phase 2 clinical trial with SLATE until 2024.
05 Nov 2020 According to a Gritstone Oncology media release, data from this study is expected in the second half of 2021
24 Jun 2020 According to a Gritstone Oncology media release, the company announced that the company will host an investor teleconference and webcast on July 13, 2020 at 8:00 a.m. ET where phase 2 study plans will also be discussed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com